Transcriptomic Biomarker Analysis – Alzheimer’s Disease

Alzheimer’s disease is a complex neurodegenerative disorder, often challenging to diagnose early. Gene expression analysis helps to better understand underlying biological mechanisms, identify early biomarkers, and target innovative therapies.

Genes Analyzed in Alzheimer’s Disease

Our panel targets key genes involved in neurodegenerative processes, inflammatory response, and signaling pathways related to Alzheimer’s, including:
APP (Amyloid Precursor Protein) – A key marker in amyloid plaque formation
PSEN1 & PSEN2 (Presenilins) – Mutations associated with familial Alzheimer’s disease
APOE – Alleles (ε2, ε3, ε4) influencing genetic risk for the disease
TREM2 – A gene involved in brain immune response and amyloid plaque phagocytosis
MAPT (Tau) – A gene linked to tau filament formation, a key pathological marker
BIN1 – A gene implicated in intracellular trafficking and neurodegeneration

Applications & Benefits

• Identifying patients at risk of developing Alzheimer’s disease

• Monitoring transcriptomic changes associated with disease progression

• Early detection of Alzheimer’s before clinical symptoms appear

• Identifying new therapeutic targets for innovative treatments

Technologies Used

We employ advanced approaches to ensure precise and reproducible analysis:

• RT-qPCR and RNA-seq (NGS) to detect specific transcriptomic alterations

• Nanostring and transcriptomic arrays for targeted biomarker analysis

• Gene expression studies focusing on neuroinflammatory processes

Contact us at contact@genxmap.com for a personalized analysis and a deeper understanding of biomarkers in Alzheimer’s disease!